1-20 of 29
Carsten Denkert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial

Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, Andrea Herencia-Ropero, Peter A. Fasching, Thomas Karn, Frederik Marmé, Peter Klare, Volkmar Müller, Andrea Stefek, Christian Schem, Christoph Uleer, Tanja Fehm, Gabriele Doering, Elmar Stickeler, Marion van Mackelenbergh, Bärbel Felder, Valentina Nekljudova, Judith Balmaña, Carsten Denkert, Sibylle Loibl, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (5): 808–814.
https://doi.org/10.1158/1078-0432.CCR-24-3148
Published: 03 March 2025
View article titled, RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A <em>Post Hoc</em> Analysis of the GeparOLA Trial
Open the PDF for RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A <em>Post Hoc</em> Analysis of the GeparOLA Trial in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative BC and HRD –long-term survival of the GeparOLA study

Peter A. Fasching, Sabine Schmatloch, Jan Hauke, Julia Rey, Christian Jackisch, Peter Klare, Theresa Link, Claus Hanusch, Jens Huober, Andrea Stefek, Johannes Holtschmidt, Andreas Schneeweiss, Christoph Uleer, Wolfgang D. Schmitt, Gabriele Doering, Kerstin Rhiem, Carsten Denkert, Rita K. Schmutzler, Christine Solbach, Eric Hahnen, Andreas Hartkopf, Michael Untch, Vesna Bjelic-Radisic, Valentina Nekljudova, Jens-Uwe Blohmer, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-2806
Published: 25 February 2025
View article titled, Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative BC and HRD –long-term survival of the GeparOLA study
Open the PDF for Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative BC and HRD –long-term survival of the GeparOLA study in another window
Includes: Supplementary data
Journal Articles

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3868–3880.
https://doi.org/10.1158/1078-0432.CCR-24-0459
Published: 03 September 2024
View article titled, An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Open the PDF for An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials in another window
Includes: Supplementary data
Journal Articles

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Theresa Link, Jens-Uwe Blohmer, Wolfgang D. Schmitt, Jan Dominik Kuhlmann, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Marc Thill, Mattea Reinisch, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Bruno V. Sinn, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4606–4612.
https://doi.org/10.1158/1078-0432.CCR-23-1801
Published: 14 November 2023
View article titled, RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Open the PDF for RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial in another window
Includes: Supplementary data
Journal Articles

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Terence M. Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A. Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher W. Szeto, Marion T. van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Thomas Mairinger, Volkmar Müller, Frederik Marme, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3384–3394.
https://doi.org/10.1158/1078-0432.CCR-23-0362
Published: 01 September 2023
View article titled, Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Open the PDF for Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmöller, Volkmar Mueller, Frederik Marmé, Patrick Soon-Shiong, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2456–2465.
https://doi.org/10.1158/1078-0432.CCR-22-2213
Published: 05 July 2023
View article titled, Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Open the PDF for Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1569–1581.
https://doi.org/10.1158/1078-0432.CCR-22-1989
Published: 14 April 2023
View article titled, Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Open the PDF for Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

Kim R.M. Blenman, Michal Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y. Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2587–2597.
https://doi.org/10.1158/1078-0432.CCR-21-3215
Published: 13 June 2022
View article titled, Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Open the PDF for Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Bruno V. Sinn, Sibylle Loibl, Claus A. Hanusch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2584–2591.
https://doi.org/10.1158/1078-0432.CCR-20-3113
Published: 01 May 2021
View article titled, Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Open the PDF for Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial

Marianne Sinn, Bruno V. Sinn, Denise Treue, Ulrich Keilholz, Frederik Damm, Rosa Schmuck, Philipp Lohneis, Frederick Klauschen, Jana K. Striefler, Marcus Bahra, Hendrik Bläker, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Hanno Riess, Jan Budczies, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3732–3739.
https://doi.org/10.1158/1078-0432.CCR-19-3034
Published: 15 July 2020
View article titled, <em>TP53</em> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial
Open the PDF for <em>TP53</em> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial in another window
Includes: Supplementary data
Journal Articles

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1896–1904.
https://doi.org/10.1158/1078-0432.CCR-19-1954
Published: 15 April 2020
View article titled, A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Open the PDF for A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial in another window
Includes: Supplementary data
Journal Articles

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Sibylle Loibl, Denise Treue, Jan Budczies, Karsten Weber, Albrecht Stenzinger, Wolfgang D. Schmitt, Wilko Weichert, Paul Jank, Jenny Furlanetto, Frederick Klauschen, Thomas Karn, Nicole Pfarr, Gunter von Minckwitz, Markus Möbs, Christian Jackisch, Christine Sers, Andreas Schneeweiss, Peter A. Fasching, Christian Schem, Michael Hummel, Marion van Mackelenbergh, Valentina Nekljudova, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3986–3995.
https://doi.org/10.1158/1078-0432.CCR-18-3258
Published: 01 July 2019
View article titled, Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Open the PDF for Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor

Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3358–3365.
https://doi.org/10.1158/1078-0432.CCR-17-2947
Published: 15 July 2018
View article titled, Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Open the PDF for Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor in another window
Includes: Supplementary data
Journal Articles

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response

Alexander Muckenhuber, Anne Katrin Berger, Anna Melissa Schlitter, Katja Steiger, Björn Konukiewitz, Andreas Trumpp, Roland Eils, Jens Werner, Helmut Friess, Irene Esposito, Günter Klöppel, Güralp O. Ceyhan, Moritz Jesinghaus, Carsten Denkert, Marcus Bahra, Albrecht Stenzinger, Martin R. Sprick, Dirk Jäger, Christoph Springfeld, Wilko Weichert
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 351–359.
https://doi.org/10.1158/1078-0432.CCR-17-2180
Published: 15 January 2018
View article titled, Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Open the PDF for Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response in another window
Includes: Supplementary data
Journal Articles

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit M. Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter A. Fasching, Hans Tesch, Christine Solbach, Mahdi Rezai, Dirk M. Zahm, Frank Holms, Manfred Glados, Petra Krabisch, Esther Heck, Angelika Ober, Petra Lorenz, Kurt Diebold, Jörg-Olaf Habeck, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5747–5754.
https://doi.org/10.1158/1078-0432.CCR-15-2338
Published: 30 November 2016
View article titled, Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Open the PDF for Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohée, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiriou, René Bernards
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5238–5248.
https://doi.org/10.1158/1078-0432.CCR-15-2996
Published: 31 October 2016
View article titled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Open the PDF for Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-15-0965
Published: 31 May 2016
View article titled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study

Frederick Klauschen, Stephan Wienert, Wolfgang D. Schmitt, Sibylle Loibl, Bernd Gerber, Jens-Uwe Blohmer, Jens Huober, Thomas Rüdiger, Erhard Erbstößer, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gunter von Minckwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3651–3657.
https://doi.org/10.1158/1078-0432.CCR-14-1283
Published: 13 August 2015
View article titled, Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study
Open the PDF for Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study in another window
Includes: Supplementary data